Amgen has argued that the FTC’s case is based on a flawed analysis of the market and that the deal would not harm competition. The company has said it is confident the court will approve the transaction.
The judge’s decision will be closely watched by the pharmaceutical industry, which has seen a flurry of mergers and acquisitions in recent years. If the deal is blocked, it could signal a tougher stance by the FTC on large pharmaceutical deals.